THC
CB1 agonist.
Listen: research reviews
Short AI-narrated discussions of the evidence on THC. Press play or read the transcript.
Read transcript
Speaker 1...and the interesting thing about THC, beyond its pain-relieving effects, is its potential connection to biological aging and even all-cause mortality.
Speaker 2Right. We know chronic, unrelieved pain itself can accelerate aging. For example, a GeroScience study from 2025 found painful diabetic neuropathy was associated with accelerated epigenetic aging and telomere shortening compared to painless neuropathy. So, pain treatment is crucial.
Speaker 1Absolutely. The question then becomes, what are the long-term trade-offs for a CB1 agonist like THC? While it can offer significant pain relief for appropriate patients under supervision, the evidence on its direct impact on biological aging markers or all-cause mortality is still developing.
Speaker 2And that’s key – “still developing.” We’ve seen concerns arise in some populations regarding long-term harms like increased risk of falls, sedation, cognitive impairment, or potential dependence, which can indirectly affect longevity and quality of life.
Speaker 1Precisely. For individuals who genuinely benefit from THC for pain management, those benefits are real. But the specific, direct mechanistic links between chronic THC use and, say, inflammation markers tied to epigenetic aging, or a definitive change in all-cause mortality rates, haven't been clearly established with robust, long-term human trials.
Speaker 2So, it's a balance. Treating pain is vital to avoid its own pro-aging effects, but the full picture of THC’s long-term biological impact, beyond immediate symptom relief, is still very much an area of active research. We don’t have all the answers yet regarding its direct effect on how our bodies age.